Proviral role of human respiratory epithelial cell‐derived small extracellular vesicles in SARS‐CoV‐2 infection

Archive ouverte

Berry, François | Morin-Dewaele, Margot | Majidipur, Amene | Jamet, Thibaud | Bartier, Sophie | Ignjatovic, Eva | Toniutti, Donatella | Gaspar Lopes, Jeanne | Soyeux-Porte, Pascale | Maillé, Pascale | Saldana, Carolina | Brillet, Rozenn | Ahnou, Nazim | Softic, Laurent | Couturaud, Benoit | Huet, Éric | Ahmed-Belkacem, Abdelhakim | Fourati, Slim | Louis, Bruno | Coste, André | Béquignon, Émilie | de la Taille, Alexandre | Destouches, Damien | Vacherot, Francis | Pawlotsky, Jean‐michel | Firlej, Virginie | Bruscella, Patrice

Edité par CCSD ; Taylor & Francis -

International audience. Abstract Small Extracellular Vesicles (sEVs) are 50–200 nm in diameter vesicles delimited by a lipid bilayer, formed within the endosomal network or derived from the plasma membrane. They are secreted in various biological fluids, including airway nasal mucus. The goal of this work was to understand the role of sEVs present in the mucus (mu‐sEVs) produced by human nasal epithelial cells (HNECs) in SARS‐CoV‐2 infection. We show that uninfected HNECs produce mu‐sEVs containing SARS‐CoV‐2 receptor ACE2 and activated protease TMPRSS2. mu‐sEVs cleave prefusion viral Spike proteins at the S1/S2 boundary, resulting in higher proportions of prefusion S proteins exposing their receptor binding domain in an ‘open’ conformation, thereby facilitating receptor binding at the cell surface. We show that the role of nasal mu‐sEVs is to complete prefusion Spike priming performed by intracellular furin during viral egress from infected cells. This effect is mediated by vesicular TMPRSS2 activity, rendering SARS‐CoV‐2 virions prone to entry into target cells using the ‘early’, TMPRSS2‐dependent pathway instead of the ‘late’, cathepsin‐dependent route. These results indicate that prefusion Spike priming by mu‐sEVs in the nasal cavity plays a role in viral tropism. They also show that nasal mucus does not protect from SARS‐CoV‐2 infection, but instead facilitates it.

Consulter en ligne

Suggestions

Du même auteur

Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells

Archive ouverte | Majidipur, Amene | CCSD

International audience. In early 2020, the novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and rapidly propagated worldwide causing a global health emergency. S...

Desloratadine, an FDA-approved Cationic Amphiphilic Drug, Inhibits SARS-CoV-2 Infection in Cell Culture and Primary Human Nasal Epithelial Cells by Blocking Viral Entry

Archive ouverte | Morin-Dewaele, Margot | CCSD

International audience. The 2019 global coronavirus (COVID-19) pandemic has brought the world to a grinding halt, highlighting the urgent need for therapeutic and preventive solutions to slow the spread of emerging ...

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)

Archive ouverte | Softic, Laurent | CCSD

International audience. Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alis...

Chargement des enrichissements...